New Triple-Drug attack on aggressive leukemia shows promise in major trial
NCT ID NCT07407140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a three-drug combination (venetoclax, azacitidine, and gilteritinib) followed by strong chemotherapy works better than standard chemotherapy plus gilteritinib for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 people aged 14 to 74 who are healthy enough for intensive treatment will take part. The goal is to see if the new approach helps patients live longer without the cancer coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can targeted drug cocktails erase hidden leukemia cells?
- Could early comfort care change End-of-Life for blood cancer patients?
- New cocktail targets tough leukemia mutations
- Immune cells take on tough leukemia in early trial
- Blood transfusions guided by how you feel, not just lab numbers
- What matters most? new study puts quality of life first for older leukemia patients